A Randomized, Double-Blind, Active-Controlled, Parallel Group, Stratified, Multi-Center, 12-Week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm 100/10 microg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Fluticasone (100 microg Twice Daily) and Formoterol (10 microg Twice Daily) Alone in Adolescent and Adult Patients With Mild to Moderate Asthma.

Trial Profile

A Randomized, Double-Blind, Active-Controlled, Parallel Group, Stratified, Multi-Center, 12-Week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm 100/10 microg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Fluticasone (100 microg Twice Daily) and Formoterol (10 microg Twice Daily) Alone in Adolescent and Adult Patients With Mild to Moderate Asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2011

At a glance

  • Drugs Fluticasone propionate; Formoterol; Formoterol/fluticasone propionate
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors SkyePharma AG
  • Most Recent Events

    • 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
    • 30 Apr 2008 Status changed from in progress to completed, following the announcement that the primary endpoints had been met.
    • 02 Nov 2007 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top